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IntroductIon
Hepatocellular carcinoma (HCC) is a global health problem and constitutes the main cause 
of death among cirrhotic patients [1,2]. The best treatment option is liver transplantation, 
which is, however, difficult to implement for lack of donors. So surgical resection represents 
the first choice treatment, but it is not always feasible due to tumor size, number of nodules, 
location, comorbidities, and the progressive deterioration of liver function in patients with 
cirrhosis [2]. Percutaneous ablation represents the most widely used treatment for patients at 
early stage who are not suitable to surgery or liver transplantation [3]. Over the years, several 
techniques for loco-regional ablation have been developed for the treatment of HCC. In par-
ticular, several thermal ablative procedures have been developed for the treatment of HCC, 
like Laser Thermal Ablation (LTA) and Radiofrequency Ablation (RF). The thermal ablative 
techniques have gained an increasing role due to their efficacy in terms of avoided local recur-
rence and prolonged Overall Survival (OS) [4]. Furthermore, these therapies destroy only a 
small part of liver parenchyma and reduce the surgical complications [5]. RF ablation is un-
doubtedly the most widely employed and studied technique [6]; the radiofrequency-generated 
heat for ionic agitation devastates the tumoral tissue [7]. However, this mechanism of action 
could decrease the efficacy of the procedure [8]. LTA has recently undergone significant dif-
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AbstrAct
BACKGROUND: Over the last decade of years, minimally invasive techniques have been developed for the treatment of 
hepatocellular carcinoma and liver metastases. We sought to investigate the health costs associated with the management 
of patients with hepatocellular carcinoma treated with radiofrequency vs laser thermal ablation and their clinical outcomes.
METHODS: We performed a retrospective analysis of the ablations performed in two referral centers in southern Italy, from 
2009 to 2013. Resource use was valued by year 2017 official prices, in €. Direct healthcare costs (drugs, visits, tests and 
hospitalizations) of different ablation techniques were compared. Total costs were analyzed from Italian NHS perspective.
RESULTS: A total of 140 patients were identified. Baseline demographics and clinical outcomes of interest did not differ 
between the two groups. Patients treated with laser thermal ablation resulted in an expected annually cost savings of 258.9 
€ per patient, in one-year follow-up healthcare costs compared with radiofrequency. The largest components of annual 
medical expenditures were attributable to drugs, regardless of the type of ablative technique.
CONCLUSIONS: The ablation using either laser thermal ablation or radiofrequency is equally effective. Laser thermal 
ablation would carry disposable cost savings as compared to radiofrequency. The costs associated with management of pa-
tients with hepatocellular carcinoma, treated with laser thermal ablation were lower than those treated with radiofrequency 
ablation. 
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fusion, although less investigated than RF: several retrospective and prospective studies have 
shown that LTA is a safe, feasible and effective procedure for the treatment of HCC [9-13]. 
LTA uses the interaction between light energy and tissue. It damages the tumoral tissue with a 
thermal destruction due to light converted to heat [14]. Some evidence from literature showed 
no difference regarding efficacy between LTA and RF [13], therefore, in absence of clear 
clinical benefit it may be interesting to focus on the resource use associated with the available 
techniques. Regardless of the benefits, LTA and RF lead to substantial financial implications. 
However, a comprehensive picture of the clinical and economic impact of HCC patients, un-
dergoing RF or LTA is still lacking. This analysis aimed to estimate the efficacy and one-year 
follow-up healthcare costs of RF and LTA in patients with HCC.
Methods
Patients
From January 2009 to September 2013, adult patients with a new diagnosis of HCC treat-
ed with RF or LTA were recruited in two referral centres in southern Italy (the Gastroenterol-
ogy Unit of the University of Naples “Federico II” and the Liver Unit of the “A. Cardarelli” 
Hospital of Naples). The analysis was performed in accordance with the principles of the 
Declaration of Helsinki and its appendices. During data collection process, the information 
was already available in hospital records. Data were analyzed with a unique and anonymous 
personal identification code. Therefore, neither ethical committee approval nor informed con-
sent forms were required. The analysis was a retrospective, observational series. Inclusion 
criteria were as follows: 1) new diagnosis of HCC; 2) naïve to treatment; 3) age 18 years or 
older; 4) at least 1 year of follow-up. Demographic characteristics and clinical parameters at 
baseline, including age, sex, Body Mass Index (BMI), aetiology of liver disease, presence of 
cirrhosis, presence of portal hypertension, Child-Pugh-Turcotte (CPT) class, Model For End-
Stage Liver Disease (MELD) score, gross pathology, extrahepatic diffusion of HCC, pres-
ence of portal vein thrombosis, biochemistry parameters and presence of comorbidities, were 
recorded. The diagnosis of HCC was performed according to the European Guidelines of the 
European Association For The Study Of The Liver (EASL) [2] and staged by imaging tech-
nique workup: dynamic Computer Tomography (CT), Contrast-Enhanced Ultrasonography 
(CEUS), dynamic Magnetic Resonance Imaging (MRI), thereafter combining the diagnostic 
Alpha-Fetoprotein (AFP) increase (>200 ng/ml). Number and size of nodules, vascular inva-
sion and extra-hepatic spread were evaluated.
Treatment choice
Treatment options were considered according to the Barcelona Clinic Liver Cancer 
(BCLC) staging system, its update and the recommendations released by the Italian Associa-
tion for the Study of the Liver (AISF) [15-17]. Treatment decisions were taken by a multidis-
ciplinary liver tumor Committee, and were influenced by several factors, including comor-
bidities, specific contraindications for each procedure, local transplant criteria, patient’s 
opinion and physician judgement. The RF or LTA procedure was subsequently decided, once 
the surgical curative treatment or radiologic intervention had been ruled out. Both procedures 
were performed percutaneously under conscious sedation and ultrasound guidance. Other de-
tails about two techniques are reported in Table I. Only operators with >5 years of experience 
in percutaneous ablations were admitted. Before percutaneous procedures, patients were hos-
pitalized for 2 days unless complications occurred.
Assessment of treatment effectiveness and follow-up
All patients were followed-up for one year since the performance of each treatment with 
clinical, laboratoristic and imaging evaluation (ultrasonography, CT or MRI) performed at 
intervals of 4-12 weeks in relation to HCC 
stage and clinical needs of the single patient. 
Response to therapy was evaluated with im-
aging techniques performed one, three, six 
and twelve months after treatment, accord-
ing to the Modified Response Evaluation 
Criteria in Solid Tumors (mRECIST) crite-
ria [18]. Based on the imaging results, tumor 
ablation and thus response to treatment were 
defined as complete when there was disap-
pearance of all signs of lesion and no patho-
Parameter RF LTA
Carriage Single electrode Laser fibers
Ablation time 10-12 minutes [13] 4-6 minutes [13]
Needle size 17-G [13] 21-G [13]
Mechanism 
of action
Joule effect (heating of 
tissues via ionic vibrations)
High-frequency thermic 
coagulation
Table i. Comparison between radiofrequency (RF) and laser thermal ablation 
(LTA) techniques
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logical enhancement was detectable on the edges of the treated area. Ablation was considered 
partial or incomplete in the case of a partial destruction of the lesion, with a reduction of at 
least 30% of the volume; in the case of incomplete ablation, a second treatment was carried 
out during the following 2 weeks. The medium-term results were assessed according to local 
progression of disease, meaning the presence of enhancement in proximity to the ablation site 
and the onset of new lesions at a distance.
Complications
According to the classification of the International Society of Radiology [19], complica-
tions were defined major if substantial morbidity, disability, care, hospitalization with a pro-
longed hospital stay occurred. Otherwise, complications were defined as minor. Other events 
was investigated during the first 48h after treatment.
statistical analysis
The demographic and clinical patients’ characteristics and costs related to different sur-
gery options was collected. Descriptive statistical analysis of the involved patient for all cat-
egories were described with means as the central tendency parameter and minimum and maxi-
mum values as dispersion parameters. A regression analysis was also performed to control 
for potential confounders. The choice of these confounding variables was made according 
to knowledge of clinical expert. For all statistical comparisons, a level of p-value < 0.05 was 
accepted as statistically significant. All statistical analyses were performed using R software/
environment.
Pharmacoeconomic analysis
Healthcare costs were analysed from the perspective of the Italian NHS. Four main cost 
categories related to the management of patients with HCC were identified: monitoring test, 
procedure attributable to the disease and surgical techniques, visit and drug. For analysis of 
costs, means (minimum-maximum) were used as central tendency parameter, expressed as 
 LTA (n. = 70) RF (n. = 70) p-value
Age, years mean ± SD 73.6 ± 9.2 73.5 ± 7.9 0.621
Male, n. (%) 47 (67.1) 54 (77.1) 0.187
Cirrhosis, n. (%) 64 (91.4) 63 (90.0) 0.771
Liver disease etiology, n. (%)
 • HCV infection 58 (82.9) 50 (71.4) 0.107
 • HBV infection 8 (11.4) 13 (18.6) 0.237
 • Others 4 (5.7) 7 (10.0) 0.215
Presence of diabetes, n. (%) 20 (28.6) 20 (28.6) 1.000
Child-Pugh Class, n. (%)1
 • A 64 (91.4) 65 (92.8) 0.753
 • B 5 (7.1) 4 (5.7) 0.730
 • C - - -
MELD score < 10, n. (%) 49 (70.0) 47 (67.1) 0.716
Diagnosis on surveillance, n. (%) 45 (64.3) 29 (41.4) 0.007
HCC morphology, n. (%)
 • Single nodule 59 (84.3) 60 (85.7) 0.8129
 • Multinodular 11 (15.7) 10 (14.3)
Largest nodule size, mm mean ± SD 28.34 ± 9.6 25.56 ± 6.5 0.1361
BCLC Class, n. (%)
 • A 64 (91.4) 58 (82.9)
0.1298
 • B 6 (8.6) 12 (17.1)
 • C - -
 • D - -
Table ii. Baseline characteristics of patients
1 2/140 patient data not available
BCLC: Barcelona Clinic Liver Cancer; HBV: Hepatitis B virus; HCC: Hepatocellular Carcinoma; HCV: Hepatitis C virus; LTA: Laser Thermal Ablation; MELD: 
Model For End-Stage Liver Disease; RF: Radiofrequency; SD Standard Deviation
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mean cost per patient per year. To concert these data to monetary terms, we multiplied the 
amount of resources consumed. The calculation is:
Fixed unit cost * Number of annual units = Total cost
Their unit cost derived from tariffs or prices applicable in Italy in 2017. In particular, 
medical costs were quantified using prices tariffs paid by the NHS: the Italian Drug Agency 
price list was used for drug costs [20]. Costs for outpatient services were obtained from na-
tional tariffs [21]. Consumption of resources related with direct costs was expressed as the 
frequency of cost items occurring in the different subgroup of patients.
results
sample description
From January 2009 to September 2013, 140 consecutive patients with a diagnosis of HCC 
were recruited and treated. Baseline characteristics of the enrolled patients are detailed in Table 
II. Demographics, clinical and disease-stage characteristics were comparable between the two 
groups. The mean age of our populations was 73 years (range 44-90 years), two/third of them 
were males and more than 90% of them had a cirrhosis. The main cause of the liver disease was 
Hepatitis C Virus (HCV) infection. Most of them showed a well-compensated liver disease 
(more than 90%) and an early stage HCC with only one nodule. The mean nodule diameter 
was 27.14 mm; however, the nodule diameter was smaller than 20 mm in 43 patients (30.7%), 
between 21-50 mm in 96 patients (68.6%), and larger than 50 mm only in 1 patient (7.1%).
Treatment analysis
Treatment analysis results of the two techniques are detailed in Table III. Patients were 
treated to either RF (70 patients, with a total of 81 nodules) or LTA (70 patients, with a total 
of 81 nodules). For treating each nodule, one RF needle/nodule and a mean of 3.8 LTA fibers/
nodule were used. No procedure was interrupted in each group. None of the patients in both 
groups showed intra- and post-procedural complications. The mean hospital stay was similar 
in the two groups with a mean value of 1.7 days per patient. According to the mRECIST cri-
teria, a complete response was obtained and maintained at 12th month in 65.7% of lesions 
treated with RF and 55.7% of those treated with LTA. The HCC recurrence within one year 
after treatment was observed in 40.0% of LTA patients and in 32.9% of RF ones, after a mean 
time of 9 months in both groups. The one year mortality rate was similar in both groups (1.4% 
LTA vs 2.1% RF). Not statistically significant differences were obtained in measured out-
comes. Overall, the efficacy was comparable between the two techniques.
Cost analysis
A Cost Minimization Analysis (CMA) was performed to compare the costs of two equally 
effective competing treatment strategies, since they have comparable clinical outcomes. One-
year follow-up healthcare costs were slightly higher for RF compared to LTA (Table IV). The 
expected costs for a patient who underwent 
ablation of HCC with RF, within one year to-
taled € 1,209.0. Patients who underwent LTA 
incurred the lower costs (€ 949.9) (p<0.341). 
A positive trend towards one-year follow-up 
healthcare costs was observed for patients 
treated with LTA, compared with RF (Figure 
1A), although the difference in values was not 
statistically significant: the mean difference 
resulted in an expected annually cost savings 
was € 258.9 per patient treated with LTA, 
compared with RF. The largest components 
of annual medical expenditures for patients 
treated with RF are drugs (46.7%), proce-
dures (40.2%), monitoring tests (10.4%) and 
visits (2.7%). For patient treated with LTA, 
the main cost item was procedures (55.5%), 
followed by drugs (21.1%), monitoring tests 
(13.2%) and visits (13.2%) (Figure 1B).
 LTA RF p-value
Patients treated, n. 70 70
Nodules treated, n. 81 81
Overall needles/devices used 3.8 fibers 1.0 needle
Adverse events to procedure, n. 0 0
Hospital stay, days mean (SD) 1.8 (0.5) 1.7 (0.6) 0.789
Patients with complete response 
at 12th month, n. (%)
39 (55.7) 46 (65.7) 0.226
Nodules with complete response 
at 12th month, n. (%)
41(58.6) 53(75.7) 0.349
Patients with 1 year recurrence 
rate, n. (%)
28 (40.0) 23 (32.9) 0.379
Mean time to recurrence, months 9.0 9.3 0.367
1-year mortality rate, % 1.4 2.1 0.649
Table iii. Treatments characteristics
LTA: Laser Thermal Ablation; RF: Radiofrequency; SD: Standard Deviation
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Presence of cirrhosis, Child-Pugh score and Meld score were selected as variables po-
tentially related with total direct costs. Figure 2 shows the one year follow-up healthcare 
costs estimated in each group of patients. The cost management of patients treated with LTA 
resulted the least costly treatment, compared to RF. Patients without cirrhosis, on average, 
Cost item, mean 
(min-max)
Cost (€)
RF LTA p-value
Monitoring tests 125.7 (80.46-268.20 ) 125.29 (26.82-268.20) 0.950
Procedures 485.51 (218.50-842.50) 527.01 (158.00-840.30) 0.030
Visits 33.30 (0.00-2,091.00) 96.88 (0.00 -6,162.00) 0.495
Drugs 564.24 (7.48-13,090.00) 200.73 (7.48-1,672.00) 0.916
Total 1209.00 (454.50-13,440.00) 949.91 (502.80-6,793.00) 0.341
Table iV. One-year follow-up healthcare costs
LTA: Laser Thermal Ablation; RF: Radiofrequency
Figure 1. Differential cost analysis (A) and resources’ type (B)
LTA: Laser Thermal Ablation; RF: Radiofrequency
Figure 2. Direct costs in selected patients’ subgroup
LTA: Laser Thermal Ablation; MELD: Model For End-Stage Liver Disease; RF: Radiofrequency
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reported one year follow-up healthcare costs for LTA approximately three times lower than 
what expenditures would be after RF. From the regression model, no variables were signifi-
cantly related to costs.
dIscussIon
HCC affected up to a million people per year worldwide [22]. New techniques are cur-
rently available in the treatment of HCC but solid evidences concerning their effectiveness 
and their pharmacoeconomic aspects have yet to be clarified. The objective of this analysis 
was to estimate the efficacy of RF and LTA and the one year follow-up costs of patients 
treated with either of two techniques. According with literature, our analysis found LTA and 
RF to be equally effective [4,8,22]. Given the equivalent outcome, the CMA was used to ana-
lyze the one year follow-up healthcare costs of patients treated with RF and LTA. The costs 
of management of patient post discharge may offer additional insight into decision making, 
given that economic evaluations about RF and LTA, in HCC are scarce. Di Costanzo et al. 
[13] reported only the price of the devices and concluded that LTA resulted cheaper than RF 
(€ 90,000 vs. € 144,000). The wide range variation in the costs could be attributed to number 
of devices and needles used. In France, Tapper et al. [23] estimated the cost of reimbursement 
paid to hospitals, under the French perspective Payment System. Based on setting used, the 
cost of RF in patients with HCC and HCV ranged from € 1,585 to € 12,967, for surgery per-
formed in outpatient setting and in inpatient setting, respectively. However, in Italy no differ-
ences were reported for inpatient reimbursement, between patient with HCC treated with RF 
or LTA. Therefore, our analysis reported the cost of patients treated with RF or LTA, during 
one year of follow-up and defined the LTA as the cheapest alternative, regarding the manage-
ment of patient. The increase of procedure cost in patients treated previously with LTA, was 
partially offset by the decrease in other costs.
This analysis has some potential limitations. First, the sample size is relatively small and 
therefore solid conclusions about the efficacy of RF and LTA cannot be done. The results 
may not be generalizable to patients with HCC in other centers or Countries, therefore they 
will need to be externally confirmed. According with perspective adopted, indirect costs were 
not included in the analysis. Another limitation is the relatively short follow-up time, which 
could preclude an evaluation of longer-term outcomes. However, this is the first analysis that 
estimates the efficacy of LTA and RF for treatment of HCC and costs associated with manage-
ment of these patients. Future researches on patients with HCC treated with the most recent 
ablative techniques should be aim to provide a real estimation of resource use reported by the 
patients, and to associate this impact with the different characteristics over long-term horizon.
conclusIons
The study showed similar efficacy between LTA and RF for the treatment of patients with 
HCC. However, the pharmacoeconomic analysis suggested that LTA could be a less costly al-
ternative, compared with RF. This paper could provide some suggestions for future analyses. 
Comparative pharmacoeconomic studies in addition to clinical evidences are needed for more 
efficient use of resources in the management of patients with HCC.
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